Sugi Predict

Sugi Predict / Compounds / SCHEMBL21354092

SCHEMBL21354092

SCHEMBL21354092

COc1ccc(-c2nnc(-c3ccc4nc(-c5c(C)cc(CC(C)(C)C(=O)O)cc5C)[nH]c4c3)o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 6/20 1.00
▸ GUSB P08236 3/20 0.44
▸ CHEK2 O96017 4/20 0.43
▸ SLC2A1 P11166 1/20 0.43
▸ KDR P35968 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30565806 1.00 DGAT1 (1.00) DGAT1GUSBCHEK2SLC2A1KDR
SCHEMBL1252086 0.93 DGAT1 (0.87) DGAT1GUSBMEN1NPC1ALDH1A1
SCHEMBL1250481 0.93 DGAT1 (0.86) DGAT1GUSBCHEK2SLC2A1PTGDR2
SCHEMBL10299681 0.90 DGAT1 (0.81) DGAT1GUSBCHEK2KDR
SCHEMBL1252006 0.88 DGAT1 (0.78) DGAT1GUSBCHEK2
SCHEMBL1250459 0.86 DGAT1 (0.76) DGAT1GUSBCHEK2NPC1ALDH1A1
SCHEMBL1252216 0.86 DGAT1 (1.00) DGAT1GUSBCHEK2SLC2A1PTGDR2
SCHEMBL30385298 0.86 DGAT1 (1.00) DGAT1GUSBCHEK2SLC2A1PTGDR2
SCHEMBL1252392 0.85 DGAT1 (0.75) DGAT1GUSBMEN1ALDH1A1HPGD
SCHEMBL1252747 0.83 DGAT1 (0.85) DGAT1GUSBCHEK2SLC2A1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193044-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION SERLEVA, INC. 2022-06-23 — — US claimed
CN-111936137-A Compositions and methods for treating severe constipation 安济药业公司 2020-11-13 — — CN claimed
US-20190282549-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION SERLEVA, INC. 2019-09-19 — — US claimed
EP-3765012-B1 DGAT1 INHIBITORS FOR USE IN TREATING CONSTIPATION SERLEVA INC (US) 2026-03-04 — — EP disclosed
US-20260000651-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION SERLEVA INC (US) 2026-01-01 — — US disclosed
US-12343334-B2 Compositions and methods for treating severe constipation SERLEVA, INC. (US) 2025-07-01 — — US disclosed
US-20240293376-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION SERLEVA, INC. 2024-09-05 — — US disclosed
US-11819495-B2 Compositions and methods for treating severe constipation ANJI PHARMACEUTICALS INC. (US) 2023-11-21 — — US disclosed
US-11819495-B2 Compositions and methods for treating severe constipation ANJI PHARMACEUTICALS INC. (US) 2023-11-21 — — US disclosed
CN-111936137-B Compositions and methods for treating severe constipation 安济药业公司 2023-09-08 — — CN disclosed
US-20220193044-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION SERLEVA, INC. 2022-06-23 — — US disclosed
US-20220193044-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION SERLEVA, INC. 2022-06-23 — — US disclosed
US-11224590-B2 Compositions and methods for treating severe constipation ANJI PHARMACEUTICALS INC. (US) 2022-01-18 — — US disclosed
US-11224590-B2 Compositions and methods for treating severe constipation ANJI PHARMACEUTICALS INC. (US) 2022-01-18 — — US disclosed
CN-111936137-A Compositions and methods for treating severe constipation 安济药业公司 2020-11-13 — — CN disclosed
US-20190282549-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION SERLEVA, INC. 2019-09-19 — — US disclosed
US-20190282549-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION SERLEVA, INC. 2019-09-19 — — US disclosed
WO-2019178492-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION ANJI PHARMACEUTICALS INC. (US) 2019-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260000651-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION DGAT1, DGAT2, SOAT1 DGAT1 1/4885GUSB 515/4885CHEK2 4250/4885
US-11819495-B2 Compositions and methods for treating severe constipation DGAT1, DGAT2, LCAT DGAT1 1/4885GUSB 806/4885CHEK2 3019/4885
US-11224590-B2 Compositions and methods for treating severe constipation DGAT1, DGAT2, LCAT DGAT1 1/4885GUSB 806/4885CHEK2 3019/4885
US-20190282549-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION DGAT1, DGAT2, LCAT DGAT1 1/4885GUSB 806/4885CHEK2 3019/4885
US-20240293376-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION DGAT1, DGAT2, LCAT DGAT1 1/4885GUSB 806/4885CHEK2 3019/4885
US-20220193044-A1 COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION DGAT1, DGAT2, LCAT DGAT1 1/4885GUSB 806/4885CHEK2 3019/4885
US-12343334-B2 Compositions and methods for treating severe constipation DGAT1, DGAT2, LCAT DGAT1 1/4885GUSB 806/4885CHEK2 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback